Cancer Immunology, Immunotherapy

, Volume 64, Issue 7, pp 923–930 | Cite as

Cancer immunotherapy achieves breakthrough status: 12th annual meeting of the association for cancer immunotherapy (CIMT), Mainz, Germany, May 6–8, 2014

  • Björn-Philipp Kloke
  • Andrea Mahr
  • Robert A. Jabulowsky
  • Sarah Kutscher
  • Richard Rae
  • Cedrik M. Britten
Meeting Report

Keywords

CIMT 2014 Cancer immunotherapy Cancer immunology Tumor vaccination 

Abbreviations

Ab

Antibody

ACT

Adoptive cellular transfer

ADCC

Antibody-dependent cellular cytotoxicity

ATG

Anti-thymocyte globulin

BTN3A1

Butyrophilin 3A1

CAR

Chimeric antigen receptor

CIMT

Association for Cancer Immunotherapy

CIP

CIMT Immunoguiding Program

CT

Cancer–testis

CTLA-4

Cytotoxic T-lymphocyte-associated protein 4

CTL

Cytotoxic T lymphocytes

CTX

Cyclophosphamide

DNAM-1

DNAX Accessory Molecule-1

FasL

Fas ligand

IFA

Incomplete Freud’s adjuvant

IL-10

Interleukin 10

LP

Long peptides

PD-1

Programmed cell death 1

PD-L1

Programmed death-ligand 1

PGE2

Prostaglandin E2

RRG

CIMT Regulatory Research group

SP

Short peptides

Teff

T effector cells

TERS

TCR-engineered reference samples

TIGIT

T cell immunoreceptor with Ig and ITIM domains

Treg

T regulatory cells

VEGF-A

Vascular endothelial growth factor A

Notes

Acknowledgments

The authors would like to thank Christiane Wellié-Reeve (Mainz, Germany) for carefully proof reading the meeting report. Selected sessions of the CIMT meeting were made possible by research grants from the German Bundesministerium für Bildung and Forschung (BMBF Grant: 031A018). The CIMT working group CIP receives support for educational activities by the Wallace Coulter Foundation (Florida, USA).

Conflict of interest

The authors declare that they have no conflict of interest. Cedrik M. Britten has been the co-organizer of the meeting. Björn-Philipp Kloke has been the co-organizer of the CIMT Endeavour workshop.

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Björn-Philipp Kloke
    • 1
  • Andrea Mahr
    • 2
  • Robert A. Jabulowsky
    • 1
  • Sarah Kutscher
    • 2
  • Richard Rae
    • 3
  • Cedrik M. Britten
    • 1
    • 3
  1. 1.BioNTech RNA Pharmaceuticals GmbHMainzGermany
  2. 2.Immatics Biotechnologies GmbHTübingenGermany
  3. 3.TRON – Translational Oncology at the University Medical Center of the Johannes Gutenberg UniversityMainzGermany

Personalised recommendations